Box | Folder		Title
		Research Data, 1950-2008 [subseries]:
28	17-19	Miscellaneous/Unidentified Studies, undated
29	1-7	Miscellaneous/Unidentified Studies (cont'd), 1950-2005
29	8	Japanese B encephalitis, 1951-1954
29	9	Lab studies on adenovirus, pneumonia or bronchiolites, 1952-1956
29	10	Avian Japanese B encephalitis, 1953-1955
29	11	Transplacental transmission polio virus, 1954-1955
29	12	Polio chick embryo, 1955
29	13	Yale - Monkey kidney trypsinization techniques Ph colon test, 1955-1956
29	14	Experiment 2. Assay of a high titer phage stock relation of plaque count to volume of phage suspension plated, 1956
29	15	Etiology of nonbacterial respiratory disease in infancy and childhood - NIH senior fellowship grant, 1956
29	16	Serology, 1956-1957
69	9	1 RSV collation, 1956-1957 [RESTRICTED PHI POLICY]
29	17	Croup, 1956-1959
29	18	Pap virus, 1958-1959
69	11	Mycoplasma - U.S. Naval Hospital, Beaufort, S.C. - patient summaries, 1959-1960 [RESTRICTED PHI POLICY]
29	19	Respiratory viruses and mycoplasmas clinical: Pap study - Parris Island, 1959-1961
29	20	#2 neutralization tests #19, 1959-1998
29	21	Immunization, 1961-1962
69	14-15	RS vaccine study, 1962-1975 [RESTRICTED PHI POLICY]
29	22	Contribution of adenoviruses to respiratory tract illness among children, 1963
29	23	Evaluation of WI-26 human diploid fibroblast cultures for isolation of adenovirus type 4, 1963
29	24-25	Lots of vaccine - Wyeth, 1963-1968
29	26-27	Mycoplasma, 1963-1992
29	28	Ludwig adeno capsule, 1964
29	29	Respiratory viruses and mycoplasmas clinical: adeno field trials - Parris Island, 1964-1965
30	1	Respiratory viruses and mycoplasmas clinical: m. pneumonia trials - Parris Island, 1965-1966
30	2	Respiratory viruses and mycoplasmas clinical: rs attenuated strain - 2, 1965-1970
69	18	Children's Hospital contract reports, 1965-1981 [RESTRICTED PHI POLICY]
30	3	Drug protocols - Wyeth, 1966
30	4	Respir. Viruses and mycoplasmas clinical: adeno field trials other, 1966-1967
69	17	RS vaccine study, 1967 [RESTRICTED PHI POLICY]
30	5	Experimental rubella vaccine lot 12-6/6A, 1967
30	6	Myxovirus recovery from respiratory tract illness - summary tables, 1967
30	7	Camargo, Ena - RSV - paraflu III plaque, 1967-1972
30	8-13	RS vaccine - Children's Hospital of D.C., 1967-1979
30	14-16	Production protocol - adenovirus vaccine, life, oral - type 7 - Wyeth, 1968-69
30	20	RS #3 challenge of para 1 new, November 1970
30	17	RS ts 1 mutant - Jessup, 30 December 1969
30	18	Clinical research protocols, 1969-1978
30	19	RS volunteer - wild type challenge of ts1 vaccinees, 13 February 1970
30	21	DBS-IND-294 Wyeth, adenovirus vaccine, type 7, live, oral - book 2, 1970-1972
30	22	Antibody response to m. pneumoniae vaccine, 1971
30	23	RSV clinical summary - Children's Hospital, 1971
30	24	Virus-associated immunopathology animal models and implications for human diseases, c.1972
30	25	RSV primates: to RS in children, c.1972-1973
69	23	Children's Hospital - nasal washings, 1972-1974 [RESTRICTED PHI POLICY]
30	26	Lab reports, 1973
30	27	Influenza A/1968 (H3N2) virus serum hemagglutination - inhibition antibody status of children before and after the Nov. 1972-Jan. 1973 epidemic of influenza A/1972 (H3N2) in Washington, D.C., 1973
30	28	Clinical observation of infants/children receiving RS-A2, ts-1 mutant, 1973
30	29	Mycoplasma vaccine trial (OSU-1) - Naval Medical Field Research Laboratory, 1974
30	30	Safety test protocol - A/Georgia/101/74 clone 1B, 1974
30	31	RS vaccine summaries - Children's Hospital, 1974-1975
31	1	RSV primates: bovine RSV in cotton rats, owl monkeys and chimps, 1974-1993
31	2	Swine influenza - Burroughs Wellcome Research Labs, 1975-1979
31	3	Camargo, Ena - RSV, 1975-1980
31	4	Huebner tumorigenicity TS-1-E (Morris), 1976
31	5	Status of two dose trials, 1976
31	6	Safety test - parainfluenza virus type 3, strain #22311 (lot F-367), 1976
31	7	RSV primates: genetic stability - stress tests RS, 1976-1989
31	8	Safety test of influ. A/VIC/3/75 (H3N2) x ts-1 [E], clone 81C1, recomb. virus (code CF/PP/1) - Flow Labs, 1977
31	9	Lot F-486 - RSV, strain A2, TS-1 NG-16 mutant, 1977-1979
31	10	RSV primates II, 1977-1991
31	11	Attenuated influenza vaccines, 1981
31	12	Nasal washings - Children's Hospital, 1981
31	13	RSV hr mutants in primates ts in primates: guinea pig kidney cell grown RSV - pass 18 chimps, 1981
31	14	RSV primates: cotton rat RS, 1981
31	15	RSV hr mutants in primates ts in primates: chick lung cell grown RSV passage 6 - chimps, 1982
31	16	RSV primates, 1982-1993
31	17	Research labs - Merck Sharp and Dohme, 1983-1991
31	18	SV40, 1983-2001
31	19-20	Production protocols - Wyeth, 1985
31	21	RSV hr mutants in primates ts in primates: primates studies RSV, 1986-1990
31	22	Immunization: flavi and alpha viruses, 1988
31	23	Prophylactic effect antibodies, 18 October 1988
31	24	MF59 Chiron, 1989-2006
31	25	RSV vaccine testing, 1989-2006
31	26	Fourth NIH rotavirus vaccine workshop, 5-6 November 1990
31	27	RSV ICN Krugman, 1991-1993
31	28	Flavivirus vaccine research - Walter Reed-NIAID, 1991-1994
31	29-30	RSV human fob monoclones, December 1991-February 1995
31	31	CA influenza virus - Wyeth, 1992-1993
31	32	RSV - Repligen, 1993
31	33	Fab 19 MARM, 1993-1995
31	34	RSV human FABS, 5 February 1995
31	35-36	AGMK cells, karyotype, tumor tests, patent, 1994-2000
32	1-3	Bovine RV (4x) clinical trial, 1997
32	4	U.S.-Russian collaboration final report, 1997
32	5-7	TBEV LGT, 1998-2000
32	8-9	TBEV II and West Nile, 2000
32	10	History of discovery and development of successful interventions, 2000
32	11	West Nile virus, 2000-2006
32	12	Periodic dengue, West Nile, TBEV meetings, 2001
32	13-14	Dengue vaccine part II, 2001-2007
33	13	Dengue virus and West Nile virus, 2008
32	15	Dengue virus vaccine development, 2002
33	1	TBEV and Langat II, 2002
33	2	Dengue virus vaccine data, 2003
33	3	Restoration of live adenoviruses vaccine in DOD, 2003-2005
33	4-6	Negative SV40, 2004
33	7-8	Positive SV40, 2004
33	9	Dengue virus vaccine development, 2004
33	10	Clinical WN/Den4 serology immunogenicity - clinical Lat/Den4 serology immunogenicity, 2005
33	11	Dengue candidates, August 2006
33	12	Den langat, 2006